A longitudinal, prospective, multicenter observational study in patients with rheumatoid arthritis receiving tocilizumab - Michinoku tocilizumab study

(1) Clinical Rheumatology 2013, Volume 32, Issue 1, pp 123-127. The DAS28-ESR cutoff value necessary to achieve remission under the new Booleanbased remission criteria in patients receiving tocilizumab (2) Modern Rheumatology 2016, Volume 26, Issue 6, pp 828-835. Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group